We are excited about the proposed acquisition of Portola announced earlier this week and look forward to providing additional detail on the trials to expand Andexxa's indication, including the Phase 2 urgent surgery program after the transaction closes.On the right side, you can see the design of our trial, which will enroll approximately 270 COVID-19 patients suffering from severe pneumonia or acute respiratory distress syndrome, ARDS, randomized two to one versus best supportive care including allowing a background use of other drugs.